This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Narla, G. Articles by Martignetti, J. A. Search for Related Content PubMed PubMed Citation Articles by Narla, G. Articles by Martignetti, J. A.

Targeted Inhibition of the KLF6 Splice Variant, KLF6 SV1, Suppresses Prostate Cancer Cell Growth and Spread

Departments of ¹ Medicine, ² Human Genetics, ³ Oncological Sciences, and ⁴ Urology, ⁵ Pediatrics, the Mount Sinai School of Medicine, New York, New York

Requests for reprints: John A. Martignetti, Department of Human Genetics, Mount Sinai School of Medicine, 1425 Madison Avenue, New York, NY 10029. Phone: 212-659-6744; E-mail: john.martignetti{at}mssm.edu.

Prostate cancer is a leading cause of cancer death in men. Risk prognostication, treatment stratification, and the development of rational therapeutic strategies lag because the molecular mechanisms underlying the initiation and progression from primary to metastatic disease are unknown. Multiple lines of evidence now suggest that KLF6 is a key prostate cancer tumor suppressor gene including loss and/or mutation in prostate cancer tumors and cell lines and decreased KLF6 expression levels in recurrent prostate cancer samples. Most recently, we identified a common KLF6 germ line single nucleotide polymorphism that is associated with an increased relative risk of prostate cancer and the increased production of three alternatively spliced, dominant-negative KLF6 isoforms. Here we show that although wild-type KLF6 (wtKLF6) acts as a classic tumor suppressor, the single nucleotide polymorphism-increased splice isoform, KLF6 SV1, displays a markedly opposite effect on cell proliferation, colony formation, and invasion. In addition, whereas wtKLF6 knockdown increases tumor growth in nude mice >2-fold, short interfering RNA–mediated KLF6 SV1 inhibition reduces growth by 50% and decreases the expression of a number of growth- and angiogenesis-related proteins. Together, these findings begin to highlight a dynamic and functional antagonism between wtKLF6 and its splice variant KLF6 SV1 in tumor growth and dissemination.

This article has been cited by other articles:

				A. DiFeo, F. Huang, J. Sangodkar, E. A. Terzo, D. Leake, G. Narla, and J. A. Martignetti KLF6-SV1 Is a Novel Antiapoptotic Protein That Targets the BH3-Only Protein NOXA for Degradation and Whose Inhibition Extends Survival in an Ovarian Cancer Model Cancer Res., June 1, 2009; 69(11): 4733 - 4741. [Abstract] [Full Text] [PDF]

				J. Holian, W. Qi, D. J. Kelly, Y. Zhang, E. Mreich, C. A. Pollock, and X.-M. Chen Role of Kruppel-like factor 6 in transforming growth factor-{beta}1-induced epithelial-mesenchymal transition of proximal tubule cells Am J Physiol Renal Physiol, November 1, 2008; 295(5): F1388 - F1396. [Abstract] [Full Text] [PDF]

				X. Huang, X. Li, and B. Guo KLF6 Induces Apoptosis in Prostate Cancer Cells through Up-regulation of ATF3 J. Biol. Chem., October 31, 2008; 283(44): 29795 - 29801. [Abstract] [Full Text] [PDF]

				J. D. Fackenthal and L. A. Godley Aberrant RNA splicing and its functional consequences in cancer cells Dis. Model. Mech., July 1, 2008; 1(1): 37 - 42. [Abstract] [Full Text] [PDF]

				A. DiFeo, L. Feld, E. Rodriguez, C. Wang, D. G. Beer, J. A. Martignetti, and G. Narla A Functional Role for KLF6-SV1 in Lung Adenocarcinoma Prognosis and Chemotherapy Response Cancer Res., February 15, 2008; 68(4): 965 - 970. [Abstract] [Full Text] [PDF]

				J. Shi, Z. Hu, K. Pabon, and K. W. Scotto Caffeine Regulates Alternative Splicing in a Subset of Cancer-Associated Genes: a Role for SC35 Mol. Cell. Biol., January 15, 2008; 28(2): 883 - 895. [Abstract] [Full Text] [PDF]

				S. L. Friedman Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver Physiol Rev, January 1, 2008; 88(1): 125 - 172. [Abstract] [Full Text] [PDF]

				R. A. Mosig, O. Dowling, A. DiFeo, M. C. M. Ramirez, I. C. Parker, E. Abe, J. Diouri, A. A. Aqeel, J. D. Wylie, S. A. Oblander, et al. Loss of MMP-2 disrupts skeletal and craniofacial development and results in decreased bone mineralization, joint erosion and defects in osteoblast and osteoclast growth Hum. Mol. Genet., May 1, 2007; 16(9): 1113 - 1123. [Abstract] [Full Text] [PDF]

				A. DiFeo, G. Narla, J. Hirshfeld, O. Camacho-Vanegas, J. Narla, S. L. Rose, T. Kalir, S. Yao, A. Levine, M. J. Birrer, et al. Roles of KLF6 and KLF6-SV1 in Ovarian Cancer Progression and Intraperitoneal Dissemination. Clin. Cancer Res., June 15, 2006; 12(12): 3730 - 3739. [Abstract] [Full Text] [PDF]

				H.-R. Li, J. Wang-Rodriguez, T. M. Nair, J. M. Yeakley, Y.-S. Kwon, M. Bibikova, C. Zheng, L. Zhou, K. Zhang, T. Downs, et al. Two-dimensional transcriptome profiling: identification of messenger RNA isoform signatures in prostate cancer from archived paraffin-embedded cancer specimens. Cancer Res., April 15, 2006; 66(8): 4079 - 4088. [Abstract] [Full Text] [PDF]

				A. Kirschenbaum, X.-H. Liu, S. Yao, G. Narla, S. L. Friedman, J. A. Martignetti, and A. C. Levine Sex steroids have differential effects on growth and gene expression in primary human prostatic epithelial cell cultures derived from the peripheral versus transition zones Carcinogenesis, February 1, 2006; 27(2): 216 - 224. [Abstract] [Full Text] [PDF]